{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:03:22Z","timestamp":1786917802412,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The proliferation of clonal cytotoxic T\u2010cells or natural killer cells has been observed after dasatinib treatment in small studies of patients with chronic myeloid leukemia (CML).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The incidence of lymphocytosis and its association with response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib\u2010treated patients with newly diagnosed CML in chronic phase (CML\u2010CP), CML\u2010CP refractory\/intolerant to imatinib, or with CML in accelerated or myeloid\u2010blast phase were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Lymphocytosis developed in 32% to 35% of patients and persisted for &gt;12 months. This was not observed in the patients who received treatment with imatinib. Dasatinib\u2010treated patients in all stages of CML who developed lymphocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML\u2010CP with lymphocytosis were more likely to achieve major and deep molecular responses. Progression\u2010free and overall survival rates were significantly longer in patients with CML\u2010CP who were refractory to or intolerant of imatinib and had lymphocytosis. Pleural effusions developed more commonly in patients with lymphocytosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Overall, lymphocytosis occurred and persisted in many dasatinib\u2010treated patients in all phases of CML. Its presence was associated with higher response rates, significantly longer response durations, and increased overall survival, suggesting an immunomodulatory effect. Prospective studies are warranted to characterize the functional activity of these cells and to assess whether an immunologic effect against CML is detectable. <jats:bold><jats:italic>Cancer<\/jats:italic> 2016;122:1398\u20131407<\/jats:bold>. \u00a9 2016 The Authors. <jats:italic>Cancer<\/jats:italic> published by Wiley Periodicals, Inc. on behalf of <jats:italic>American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29933","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T22:18:40Z","timestamp":1458598720000},"page":"1398-1407","source":"Crossref","is-referenced-by-count":56,"title":["Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity"],"prefix":"10.1002","volume":"122","author":[{"given":"Charles A.","family":"Schiffer","sequence":"first","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"The University of Texas M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Jena University Hospital Jena Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"San Luigi Gonaga Hospital University of Turin Orbassano\u2010Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[{"name":"Charite\u2010Campus Virchow Clinic Berlin Medical University Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Research Unit Helsinki University Central Hospital Comprehensive Cancer Center, University of Helsinki Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Research Unit Helsinki University Central Hospital Comprehensive Cancer Center, University of Helsinki Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"University of California, San Francisco School of Medicine San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Sprycel","author":"Bristol\u2010Myers Squibb Company","year":"2015"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-009-0046-y"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0170"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.02.006"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.05.002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07433.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.09.007"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084814"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208160"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.2997"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00751.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V112.11.1114.1114","article-title":"A comprehensive lymphocyte analysis of dasatinib treated chronic myelogenous leukemia patients reveals T\u2010cell oligoclonality [abstract]","volume":"112","author":"Powers JJ","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21980"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.08.022"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13151"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood.V114.22.3279.3279","article-title":"T\/NK cell lymphocytosis in CML Ph\u2009+\u2009patients during dasatinib therapy [abstract]","volume":"114","author":"Russo Rossi A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V116.21.358.358","article-title":"Lymphocytosis following first\u2010line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib [abstract]","volume":"116","author":"Schiffer CA","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0565-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.46"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1132-8"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-256800"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0526-8"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.348"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1200\/jco.2010.28.15_suppl.6553","article-title":"Association of lymphocytosis following treatment with dasatinib with response and outcome [abstract]","volume":"28","author":"Schiffer CA","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_8_33_1","volume-title":"Tasigna","author":"Novartis Pharmaceuticals Corp","year":"2015"},{"key":"e_1_2_8_34_1","volume-title":"Bosulif","author":"Pfizer Inc","year":"2015"},{"key":"e_1_2_8_35_1","volume-title":"Iclusig","author":"Ariad Pharmaceuticals Inc","year":"2015"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.02.015"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474577"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114885"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28925"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29933","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.29933","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:24:37Z","timestamp":1760293477000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/cncr.29933"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29933","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]}}}